Kidney Cancer Clinical Trial

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Summary

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be:

At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants diagnosed with locally advanced or metastatic renal cell carcinoma
Participants with full medical information is available regarding all treatments before, during and after 1st line

Exclusion Criteria:

Study is for people with:

Kidney Cancer

Estimated Enrollment:

400

Study ID:

NCT05534789

Recruitment Status:

Active, not recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Pfizer New York
New York New York, 10017, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

400

Study ID:

NCT05534789

Recruitment Status:

Active, not recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider